Mese: settembre 2024

“Hepatocellular Carcinoma (HCC) Pipeline Insight 2024” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Hepatocellular Carcinoma Therapeutics Market.

The report provides a detailed description of the Hepatocellular Carcinoma drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product- related details.

Get a Detailed Overview of the Hepatocellular Carcinoma Clinical Trial Activities and Regulatory Developments in the domain @ Hepatocellular Carcinoma Companies

Hepatocellular Carcinoma (HCC) Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing Hepatocellular Carcinoma therapies.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatocellular Carcinoma treatment.

key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging Hepatocellular Carcinoma drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Hepatocellular Carcinoma treatment market.

Learn More about the Clinical and Commercial Development Activities in the Hepatocellular Carcinoma Therapeutics Domain @ Hepatocellular Carcinoma Clinical Trials

Hepatocellular Carcinoma (HCC) Therapeutics Analysis

About 90+ notable companies are actively involved in developing therapies for Hepatocellular Carcinoma (HCC). Among them, Can-Fite BioPharma stands out as a key player, advancing its HCC drug candidates to the most advanced stage, Phase III.

Hepatocellular Carcinoma Companies in the Therapeutics Market Include:

Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCap Zoom Biosciences, Eutilex, Polaris Pharmaceuticals, and OriCell Therapeutics are the leading pharma giants shaping the landscape of the Hepatocellular Carcinoma Therapeutic Market.

Emerging and Marketed Hepatocellular Carcinoma Therapies Covered in the Report Include:

• Namodenoson: Can-Fite BioPharma

• SRF388: Surface Oncology

• Porustobart: Harbor BioMed

• Fisogatinib: CStone Pharmaceuticals

• STP705: Sirnaomics

And Many Others

Get an in-depth Assessment of the Emerging Therapies and Hepatocellular Carcinoma Companies Actively Working in the Market @ Hepatocellular Carcinoma Therapies

The Report Covers the Emerging Hepatocellular Carcinoma Therapies Under Different Phases of Clinical Development Like –

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage products (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued and inactive candidates

Route of Administration

Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Request for Sample PDF to Understand More About the Hepatocellular Carcinoma Treatment Outlook and Future Perspectives @ Hepatocellular Carcinoma Treatment Outlook

Table of Content

1. Report Introduction

2. Executive Summary

3. Hepatocellular Carcinoma Current Treatment Patterns

4. Hepatocellular Carcinoma – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Hepatocellular Carcinoma Late-Stage Products (Phase-III)

7. Hepatocellular Carcinoma Mid-Stage Products (Phase -II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Hepatocellular Carcinoma Discontinued Products

13. Hepatocellular Carcinoma Product Profiles

14. Hepatocellular Carcinoma Companies

15. Hepatocellular Carcinoma Drugs

16. Dormant and Discontinued Products

17. Hepatocellular Carcinoma Unmet Needs

18. Hepatocellular Carcinoma Future Perspectives

19. Hepatocellular Carcinoma Analyst Review

20. Appendix

21. Report Methodology

Contact Info:

Ram Kapoor

Executive: Marketing & International Branding

Email: info@delveinsight.com

Contact No: +14699457679

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

“Complicated Urinary Tract Infection (UTI) Pipeline Insight 2024” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Complicated Urinary Tract Infection Therapeutics Market.

The report provides a detailed description of the Complicated Urinary Tract Infection drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Complicated Urinary Tract Infection Clinical Trial Activities and Regulatory Developments in the domain @ Complicated Urinary Tract Infection Companies

Complicated Urinary Tract Infection (UTI) Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing Complicated Urinary Tract Infection therapies.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Complicated Urinary Tract Infection treatment.

• It conglomerates the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging Complicated Urinary Tract Infection drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Complicated Urinary Tract Infection treatment market.

Learn More about the Clinical and Commercial Development Activities in the Complicated Urinary Tract Infection Therapeutics Domain @ Complicated Urinary Tract Infection Clinical Trials

Complicated Urinary Tract Infection (UTI) Therapeutics Analysis

Around 12 noteworthy companies are actively involved in the development of therapies for Complicated Urinary Tract Infections (cUTIs). Notably, Spero Therapeutics stands out among these, with its cUTI drug candidates progressing to the most advanced stage, Phase III.

Complicated Urinary Tract Infection (UTI) Companies in the Therapeutics Market Include:

Spero Therapeutics, Iterum Therapeutics, Venatorx Pharmaceuticals Inc., Nabriva Therapeutics, Allecra Therapeutics, Wockhardt, and MerLion Pharmaceuticals are notable contributors in the field of Complicated Urinary Tract Infection therapeutics, each playing a crucial role in the advancement and development of treatments within the Complicated Urinary Tract Infection market..

Emerging and Marketed Complicated Urinary Tract Infection (UTI) Therapies Covered in the Report Include:

• Tebipenem Pivoxil Hydrobromide: Spero Therapeutics

• Sulopenem: Iterum Therapeutics

And Man Others

Get an in-depth Assessment of the Emerging Therapies and Complicated Urinary Tract Infection Companies Actively Working in the Market @ Complicated Urinary Tract Infection Pipeline Insight

The Report Covers the Emerging Complicated Urinary Tract Infection Therapies Under Different Phases of Clinical Development Like –

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage products (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued and inactive candidates

Route of Administration

Complicated Urinary Tract Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy Table of Content

1. Report Introduction

2. Executive Summary

3. Complicated Urinary Tract Infection Current Treatment Patterns

4. Complicated Urinary Tract Infection – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Complicated Urinary Tract Infection Late-Stage Products (Phase-III)

7. Complicated Urinary Tract Infection Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Complicated Urinary Tract Infection Discontinued Products

13. Complicated Urinary Tract Infection Product Profiles

14. Complicated Urinary Tract Infection Companies

15. Complicated Urinary Tract Infection Drugs

16. Dormant and Discontinued Products

17. Complicated Urinary Tract Infection Unmet Needs

18. Complicated Urinary Tract Infection Future Perspectives

19. Complicated Urinary Tract Infection Analyst Review

20. Appendix

21. Report Methodology

Get Detailed Insights About the Reports Offerings @ Complicated Urinary Tract Infection Treatment Outlook

Contact Info:

Ram Kapoor

Executive: Marketing & International Branding

Email: info@delveinsight.com

Contact No: +14699457679

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

“Fabry Disease Pipeline Insight 2024” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Fabry Disease Therapeutics Market.

The report provides a detailed description of the Fabry Disease drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product- related details.

Get a Detailed Overview of the Fabry Disease Clinical Trial Activities and Regulatory Developments in the domain @ Fabry Disease Companies

Fabry Disease Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing Fabry Disease therapies.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Fabry Disease treatment

. key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging Fabry Disease drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Fabry Disease treatment market.

Learn More about the Clinical and Commercial Development Activities in the Fabry Disease Therapeutics Domain @ Fabry Disease Therapies

Fabry Disease Therapeutics Analysis

Over 18 prominent companies are currently engaged in the development of therapies for Fabry Disease. Among these, Protalix Biotherapeutics stands out as a frontrunner, with its Fabry Disease drug candidates advancing to the most advanced stage, known as Preregistration.

Fabry Disease Companies in the Therapeutics Market Include:

Idorsia Pharmaceuticals, Protalix, Sanofi Genzyme, Sangamo Therapeutics, 4D Molecular Therapeutics, Resverlogix Corp, AVROBIO, Freeline Therapeutics, Ozmosis Research Inc., CellGenTech Inc., uniQure, Codexis, Canbridge, Eleva GmbH, MP6 Therapeutics, Amicus Therapeutics, and Sigilon Therapeutics are key players actively contributing to the evolving landscape of Fabry Disease treatment.

Emerging and Marketed Fabry Disease Therapies Covered in the Report Include:

• Pegunigalsidase Alfa: Protalix Biotherapeutics

• Venglustat: Sanofi

• 4D 310: 4D Molecular Therapeutics

And Many Others

Get an in-depth Assessment of the Emerging Therapies and Fabry Disease Companies Actively Working in the Market @ Fabry Disease Clinical Trials

The Report Covers the Emerging Fabry Disease Therapies Under Different Phases of Clinical Development Like –

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage products (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued and inactive candidates

Route of Administration

Fabry Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral

• Parenteral

• Intravitreal

• Subretinal

• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Request for Sample PDF to Understand More About the Fabry Disease Treatment Outlook and Future Perspectives @ Fabry Disease Pipeline Insight

Table of Content

1. Report Introduction

2. Executive Summary

3. Fabry Disease Current Treatment Patterns

4. Fabry Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Fabry Disease Late-Stage Products (Phase-III)

7. Fabry Disease Mid-Stage Products (Phase -II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Fabry Disease Discontinued Products

13. Fabry Disease Product Profiles

14. Fabry Disease Companies

15. Fabry Disease Drugs

16. Dormant and Discontinued Products

17. Fabry Disease Unmet Needs

18. Fabry Disease Future Perspectives

19. Fabry Disease Analyst Review

20. Appendix

21. Report Methodology

Get Detailed Insights About the Reports Offerings @ Fabry Disease Treatment Outlook

Contact Info:

Ram Kapoor

Executive: Marketing & International Branding

Email: info@delveinsight.com

Contact No: +14699457679

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

The “Adenoid Cystic Carcinoma Pipeline Insights” report (published by DelveInsight) provides a comprehensive analysis of the ongoing clinical development activities and growth prospects in the adenoid cystic carcinoma treatment market.

The report provides a detailed description of Adenoid Cystic Carcinoma drugs, mechanism of action, type, stage, route of administration, molecule type, clinical trials, inactive pipeline products, and NDA approval (if applicable). It also covers commercial and clinical activities of pipeline products from preclinical development stage to commercial stage. In addition, it also profiles ongoing, collaborations, licensing, mergers and acquisitions (M&A), funding, designations developments, and other product-related details in therapeutic segments.

A detailed overview of adenoid cystic carcinoma clinical trial activity and regulatory developments is available here: Adenoid Cystic Carcinoma Companies

The Adenoid Cystic Carcinoma Pipeline Analysis report provides the following information:

• Detailed insights into the key companies developing adenoid cystic carcinoma therapeutics • Assessment of therapeutic candidates under development for adenoid cystic carcinoma treatment split into early, mid, and late stage • Analysis of key companies involved in the development of adenoid cystic carcinoma therapeutics and their associated active and inactive (dormant or discontinued) projects • Navigation of emerging adenoid cystic carcinoma therapeutics based on development stage, route of administration, target receptor, monotherapy or combination therapy, different mechanisms of action, and molecule type • Detailed analysis of collaborations (company- to-company collaborations and corporate-academic collaborations), licensing agreements, and funding for the future progress of the adenoid cystic carcinoma treatment market

For more information on clinical and commercial development activities in Adenoid Cystic Carcinoma Therapies, please visit: Adenoid Cystic Carcinoma Therapies

Adenoid Cystic Carcinoma Drugs Analysis Approximately 5000+ pharmaceutical and biotechnology companies are actively involved in the development of adenoid cystic carcinoma (ACC) drugs. Among them, certain companies have advanced their adenoid cystic carcinoma drug candidates to the most advanced stage, especially Phase III. Deerland Probiotics & Enzymes is noteworthy in this regard, demonstrating its commitment to advancing adenoid cystic carcinoma treatment solutions through innovative approaches.

Companies in the Adenoid Cystic Carcinoma Treatment market include:

• Ayala Pharmaceuticals • Cure Vac • Elevar Therapeutics • Actuate Therapeutics • Merck and many more

The emerging and marketed Adenoid Cystic Carcinoma drugs profiled in the report include:

• Rivoceranib: Elevar Therapeutics • Osugacestat: Ayala Pharmaceuticals And many more

Learn more about Adenoid Cystic Carcinoma active in the market and emerging therapeutics here: Adenoid Cystic Carcinoma Clinical Trials

The report includes emerging adenoid cystic carcinoma therapeutics in different phases of clinical development:

• Late stage products (Phase III) • Mid stage products (Phase II) • Early stage products (Phase I) • Preclinical and discovery stage candidates • Discontinued and inactive candidates

The Adenoid Cystic Carcinoma pipeline report provides a therapeutic assessment of pipeline drugs by route of administration. The products are segmented by route of administration as follows :

• Intra-articular • Intraocular • Intrathecal • Intravenous • Ophthalmic • Oral • Parenteral • Subcutaneous • Topical • Transdermal

Molecule Type Products are categorized by the following molecule types: • Oligonucleotides • Peptides • Small Molecules

For more information on the outlook and future prospects for adenoid cystic carcinoma treatment, please see: Adenoid Cystic Carcinoma Pipeline Insight

table of contents

1. Report Introduction

2. executive summary

3. Current Treatment Patterns for Adenoid Cystic Carcinoma

4. Adenoid Cystic Carcinoma – DelveInsight Analytical Perspective

5. Treatment evaluation

6. Late-stage product (Phase III) for adenoid cystic carcinoma

7. Mid-stage product (Phase II) for adenoid cystic carcinoma

8. Early Stage Products (Phase I)

9. Preclinical and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Adenoid cystic carcinoma discontinued products

13. Adenoid Cystic Carcinoma Product Profile

14. Adenoid Cystic Carcinoma Company

15. Adenoid cyst cancer drug

16. Dormant and discontinued products

17. Unmet Need for Adenoid Cystic Carcinoma

18. Future outlook for adenoid cystic carcinoma

19. Adenoid Cystic Carcinoma Analyst Review

20. appendix

21. Report Methodology

Learn more about what the report offers: Adenoid Cystic Carcinoma Treatment Outlook

Contact Information:

Ram Kapoor

Marketing & International Branding Executive

Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight

DelveInsight is a leading life science focused business consultancy and market research firm, providing comprehensive end-to-end solutions to help pharmaceutical companies improve their performance.

The market size of PD-1 Non-Small Cell Lung Cancer is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Regeneron Pharmaceuticals, Sanofi, Bavarian Nordic,, Chengdu MedGenCell Co. Ltd., Merck Sharp & Dohme LLC, Dynavax Technologies Corporation, BeiGene, Tesaro Inc., Bristol-Myers Squibb

[City, Date] – DelveInsight’s “PD-1 Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast 2032.” report offers a detailed examination of PD-1 Non-Small Cell Lung Cancer, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the PD-1 Non-Small Cell Lung Cancer Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; PD-1 Non-Small Cell Lung Cancer Market Forecast

Key Findings from the PD-1 Non-Small Cell Lung Cancer Market Report:

• The PD-1 Non-Small Cell Lung Cancer market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).

• In August, 2024: Iovance Biotherapeutics, Inc. announced a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).

• In August, 2024: Tango Therapeutics, Inc announced that the goal of their clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation.

• In August, 2024: Merck Sharp & Dohme LLC announced that a study evaluating the efficacy and safety of MK-1084 with pembrolizumab as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%.

• In August, 2024: Novartis announced that their study aims to assess the antitumor activity and safety of JDQ443 single-agent as first-line treatment for participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor a KRAS G12C mutation and a PD-L1 expression < 1% regardless of STK11 mutation status (cohort A), or a PD-L1 expression ≥ 1% and an STK11 co-mutation (cohort B).

• In August, 2024: AstraZeneca announced that their study will assess the efficacy and safety of the combination of ceralasertib and durvalumab versus standard of care docetaxel in patients with locally advanced and metastatic NSCLC after progression on prior anti-PD-(L)1 therapy and platinum-based chemotherapy.

• The total number of incident cases of NSCLC in the 7MM was nearly 524,000 cases in 2023 and is projected to increase during the forecasted period.

• In 2023, the incidence of NSCLC cases in the United States was~56% in males and~ 44% in females.

• Key PD-1 Non-Small Cell Lung Cancer Companies are as follow: MSD, Bristol-Myers Squibb/Ono Pharmaceutical, Genentech/Hoffmann-La Roche, CStone, BeiGene, Daiichi Sankyo/AstraZeneca Gilead Sciences, GlaxoSmithKline, and others

• Key PD-1 Non-Small Cell Lung Cancer Therapies are as follows: KEYTRUDA, OPDIVO, TECENTRIQ, IMFINZI, TRODELVY, TIZVENI, JEMPERLI, Sugemalimab, Datopotamab Deruxtecan, Ociperlimab, and others

• Launching multiple stage PD-1 Non-Small Cell Lung Cancer pipeline products is expected to revolutionize market dynamics, further propelling market growth.

PD-1 Non-Small Cell Lung Cancer Overview:

NSCLC is the most prevalent form of lung cancer, representing about 85% of all lung cancer cases. Unlike NSCLC, untreated SCLC can be fatal within weeks. Standard treatment outcomes for NSCLC are generally poor, except in cases where the cancer is highly localized. Patients newly diagnosed with NSCLC are potential candidates for trials exploring novel treatments. One such treatment is immune checkpoint inhibitor therapy, specifically PD-(L)1, a form of immunotherapy used to treat NSCLC. Tumor cells can overexpress PD-L1, enabling them to evade the immune system. In NSCLC, PD-(L)1 expression, measured as the percentage of viable tumor cells with membranous staining (tumor proportion score, TPS), serves as a predictive biomarker for response to immune checkpoint inhibitors.

PD-1 Non-Small Cell Lung Cancer Drugs Uptake and Pipeline Development Activities:

The drugs uptake section focuses on the rate of uptake of potential drugs recently launched or expected to be launched during the study period. The report covers market uptake by drugs, patient uptake by therapies, and sales of each drug. Additionally, it provides insights into PD-1 Non-Small Cell Lung Cancer Pipeline Development Activities, analyzing therapeutic candidates in various stages and key companies involved.

PD-1 Non-Small Cell Lung Cancer Therapies and Key Companies:

• KEYTRUDA (pembrolizumab): Merck

• OPDIVO (nivolumab): Bristol-Myers Squibb/Ono Pharmaceutical

• TECENTRIQ (atezolizumab): Genentech/Hoffmann-La Roche

• LIBTAYO (cemiplimab-rwlc): Regeneron/Sanofi

• TIZVENI (tislelizumab): BeiGene

• Sugemalimab (CS1001): CStone

• Datopotamab Deruxtecan: Daiichi Sankyo/AstraZeneca

• Ociperlimab + Tislelizumab: BieGene

• TRODELVY (sacituzumab govitecan) + pembrolizumab: Gilead Sciences

• JEMPERLI (dostarlimab): GlaxoSmithKline

For more information about PD-1 Non-Small Cell Lung Cancer companies working in the treatment market, visit PD-1 Non-Small Cell Lung Cancer Clinical Trials

PD-1 Non-Small Cell Lung Cancer Epidemiology:

The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2019 to 2032. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic PD-1 Non-Small Cell Lung Cancer.

PD-1 Non-Small Cell Lung Cancer Epidemiology Segmentation:

The PD-1 Non-Small Cell Lung Cancer market report provides epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of PD-1 Non-Small Cell Lung Cancer

• Prevalent Cases of PD-1 Non-Small Cell Lung Cancer by severity

• Gender-specific Prevalence of PD-1 Non-Small Cell Lung Cancer

• Diagnosed Cases of Episodic and Chronic PD-1 Non-Small Cell Lung Cancer

PD-1 Non-Small Cell Lung Cancer Market Drivers and Barriers:

The PD-1 Non-Small Cell Lung Cancer Market Forecast report highlights key drivers and barriers shaping the PD-1 Non-Small Cell Lung Cancer market dynamics, providing insights into factors influencing growth and challenges that may be encountered.

Scope of the PD-1 Non-Small Cell Lung Cancer Market Report:

• Study Period: 2020-2034

• Coverage: 7MM (The United States, EU5, and Japan)

• Key PD-1 Non-Small Cell Lung Cancer Companies: MSD, Bristol-Myers Squibb/Ono Pharmaceutical, Genentech/Hoffmann-La Roche, CStone, BeiGene, Daiichi Sankyo/AstraZeneca Gilead Sciences, GlaxoSmithKline, and others

• Key PD-1 Non-Small Cell Lung Cancer Therapies: KEYTRUDA, OPDIVO, TECENTRIQ, IMFINZI, TRODELVY, TIZVENI, JEMPERLI, Sugemalimab, Datopotamab Deruxtecan, Ociperlimab, and others

• PD-1 Non-Small Cell Lung Cancer Therapeutic Assessment: Current marketed and emerging therapies

• PD-1 Non-Small Cell Lung Cancer Market Dynamics: PD-1 Non-Small Cell Lung Cancer Market drivers and PD-1 Non-Small Cell Lung Cancer barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• PD-1 Non-Small Cell Lung Cancer Unmet Needs: Insights into unmet needs, KOL’s views, Analyst’s views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of PD-1 Non-Small Cell Lung Cancer market outlook, drug uptake, treatment scenario, and epidemiology trends, PD-1 Non-Small Cell Lung Cancer Market Forecast

About DelveInsight:

DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:

Company Name: DelveInsight Business Research LLP

Contact Person: Ram Kapoor

Email: info@delveinsight.com

Contact No.: +91-9650213330

City: 304 S. Jones Blvd #2432 , Las Vegas

State: Nevada (89107)

Country: United States

Website : https://www.delveinsight.com/consulting

The market size of Cryopyrin-associated Periodic Syndrome is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Zydus Cadil, Novartis, Inflazome, Roche, Aclaris Therapeutics, Mabpharm, Zomagen Biosciences, Ltd.

[City, Date] – DelveInsight’s “Cryopyrin-associated Periodic Syndrome Market Insights, Epidemiology, and Market Forecast 2032.” report offers a detailed examination of Cryopyrin-associated Periodic Syndrome, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To know in detail about the Cryopyrin-associated Periodic Syndrome Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cryopyrin-Associated Periodic Syndrome Market Forecast

Key Findings from the Cryopyrin-Associated Periodic Syndrome Market Report:

• The Cryopyrin-Associated Periodic Syndrome market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2019-2032).

• In May, 2024: Novartis announced that the purpose of their Phase 2 study is to assess the safety, tolerability and efficacy of DFV890 in participants with FCAS.

• In March, 2024: Zomagen Biosciences, Ltd announced a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Cryopyrin-Associated Period Syndrome (CAPS). Approximately 10 patients will take VTX2735 Dose A or VTX2735 Dose B.

• In 2019, the total prevalent cases of CAPS in the United States, were 674, which are anticipated to increase by 2032.

• According to Orphanet (2020), the whole spectrum of CAPS has a prevalence of 1/360,000 in France, CINCA being the less common form. Males and females are equally affected.

• According to NHS England (2013), the prevalence of CAPS is thought to be ~ 1 in 1 million in the United Kingdom.

• Key Cryopyrin-Associated Periodic Syndrome Companies are as follow: Zydus Cadil, Novartis, Inflazome, Roche, Aclaris Therapeutics, Mabpharm, Zomagen Biosciences, Ltd and more

• Key Cryopyrin-associated Periodic Syndrome Therapies are as following: VTX2735, ZYIL1 capsule, canakinumab, rilonacept, Placebo, ACZ885, DFV890

• Launching multiple stage Cryopyrin-associated Periodic Syndrome pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Cryopyrin-Associated Periodic Syndrome Overview:

Cryopyrin-associated Periodic Syndromes (CAPS) is a rare group of auto-inflammatory as well as known autosomal dominant disorder that is believed to be caused due to a mutation on the exon 3 of the NLRP3 gene which codes for Cryopyrin protein. CAPS comprises a group of three disorders, varying with their severity and the organs they tend to affect upon the onset, namely Neonatal Onset Multisystem Inflammatory Disease (NOMID), also called as Chronic Inflammatory Neurological Cutaneous Articular Syndrome (CINCA), Familial cold auto inflammatory syndrome (FCAS) and Muckle–Wells syndrome (MWS).

Cryopyrin-Associated Periodic Syndrome Drugs Uptake and Pipeline Development Activities:

The drug uptake section highlights the adoption rate of newly launched or anticipated drugs during the study period. It includes an analysis of drug market uptake, patient uptake across therapies, and individual drug sales. Moreover, it offers insights into the Cryopyrin-associated Periodic Syndrome pipeline development activities, examining therapeutic candidates at different stages and the key companies involved.

Cryopyrin-Associated Periodic Syndrome Therapies and Key Companies:

• VTX2735: Zomagen Biosciences, Ltd

• ZYIL1 capsule: Zydus Lifesciences Limited

• canakinumab, ACZ885: Novartis Pharmaceuticals

• rilonacept, Placebo: Regeneron Pharmaceuticals

For more information about Cryopyrin-Associated Periodic Syndrome companies working in the treatment market, visit Cryopyrin-Associated Periodic Syndrome Clinical Trials

Cryopyrin-Associated Periodic Syndrome Epidemiology:

The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2019 to 2032. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Cryopyrin-associated Periodic Syndrome.

Cryopyrin-Associated Periodic Syndrome Epidemiology Segmentation:

The Cryopyrin-associated Periodic Syndrome market report provides epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Cryopyrin-Associated Periodic Syndrome Total Prevalence.

• Cryopyrin-Associated Periodic Syndrome Prevalent Cases by severity

• Gender-specific Prevalence of Cryopyrin-Associated Periodic Syndrome

• Diagnosed Cases of Episodic and Chronic Cryopyrin-Associated Periodic Syndrome

Cryopyrin-Associated Periodic Syndrome Market Drivers and Barriers:

The Cryopyrin-Associated Periodic Syndrome Market Forecast report highlights key drivers and barriers shaping the Cryopyrin-Associated Periodic Syndrome market dynamics, providing insights into factors influencing growth and challenges that may be encountered.

Scope of the Cryopyrin-Associated Periodic Syndrome Market Report:

• Study Period: 2019–2032

• Coverage: 7MM (The United States, EU5, and Japan)

• Key Cryopyrin-associated Periodic Syndrome Companies: VTX2735, ZYIL1 capsule, canakinumab, rilonacept, Placebo, ACZ885, DFV890

• Key Cryopyrin-associated Periodic Syndrome Therapies: VTX2735, ZYIL1 capsule, canakinumab, rilonacept, Placebo, ACZ885, DFV890

• Cryopyrin-associated Periodic Syndrome Therapeutic Assessment: Current marketed and emerging therapies

• Cryopyrin-Associated Periodic Syndrome Market Dynamics: Cryopyrin-Associated Periodic Syndrome Market drivers and Cryopyrin-Associated Periodic Syndrome barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Cryopyrin-Associated Periodic Syndrome Unmet Needs: Insights into unmet needs, KOL’s views, Analyst’s views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Cryopyrin-associated Periodic Syndrome market outlook, drug uptake, treatment scenario, and epidemiology trends, Cryopyrin-associated Periodic Syndrome Market Forecast

About DelveInsight:

DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:

Company Name: DelveInsight Business Research LLP

Contact Person: Ram Kapoor

Email: info@delveinsight.com

Contact No.: +91-9650213330

City: 304 S. Jones Blvd #2432 , Las Vegas

State: Nevada (89107)

Country: United States

Website : https://www.delveinsight.com/consulting

The market size of Membranous Nephropathy is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as BeiGene, Reistone Biopharma Company Limited, Hoffmann-La Roche, Gilead Sciences, Mallinckrodt, Mayo Clinic, Genentech Inc., GlaxoSmithKline, Roche Pharma AG, Apellis Pharmaceuticals Inc., and others…

[Nevada, United States] – DelveInsight’s “Membranous Nephropathy Market Insights, Epidemiology, and Market Forecast 2032.” report offers a detailed examination of Membranous Nephropathy, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Membranous Nephropathy Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Membranous Nephropathy Market Forecast

Key Findings from the Membranous Nephropathy Market Report:

• The Membranous Nephropathy market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2019-2032).

• In September, 2024: Shanghai Jiaolian Drug Research and Development Co., Ltd announced that the purpose of their study is to evaluate the efficacy and safety of B007 in the Treatment of Primary Membranous Nephropathy

• In August, 2024: BeiGene announced that the primary objective of their study is to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and to evaluate the efficacy of zanubrutinib compared with tacrolimus as measured by complete remission rate, in participants with primary membranous nephropathy who are on optimal supportive care.

• In August, 2024: Hoffmann-La Roche announced that their study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants with primary membranous nephropathy (pMN).

• In August, 2024: Hansa Biopharma AB announced that a Phase 3 trial evaluating renal function in patients with severe anti-GBM disease comparing imlifidase and standard of care (SoC) with SoC alone. All patients will remain in the trial for 24 months.

• In June, 2024: Apellis Pharmaceuticals, Inc. announced that a Phase II trial assessing the safety and preliminary efficacy of daily APL-2 subcutaneous infusion administered for 16 weeks with a 6 month safety follow up, in patients with glomerulopathies

• In a study by Storrar et al. (2022), 178 patients with primary membranous nephropathy were identified over two decades. As per the results of this study, remission (partial or complete) was achieved in 134 (75.3%), either spontaneous in 60 (33.7%) or after treatment with immunosuppression in 74 (41.6%), and of these, 57 (42.5%) relapsed. Progression to renal replacement therapy was seen in 10.1%, with mortality in 29.8%.

• In 2023, the prevalent population of Idiopathic Membranous Nephropathy in the United States was found to be around 29,000, which will increase to 31,227 cases by 2034.

• Among EU4 and the UK, PLA2R and THSD7A antigens were detected in nearly 18,000 and 1,000 IMN patients, respectively.

• Key Membranous Nephropathy Companies are as follows: Argenx, Zai Lab Pty Ltd., Shanghai Jiaolian Drug Research and Development Co. Ltd., Shanghai Pharmaceuticals Holding Co., Ltd, Acelyrin, Beijing Mabworks Biotech Co., Ltd., Cerium Pharmaceuticals Inc., BeiGene, Reistone Biopharma Company Limited, Hoffmann-La Roche, Gilead Sciences, Mallinckrodt, Mayo Clinic, Genentech Inc., GlaxoSmithKline, Roche Pharma AG, Apellis Pharmaceuticals Inc., and others.

• Key Membranous Nephropathy Therapies are as follow: placebo, VB119, Rituximab, MIL62, Cyclosporine, B007, Cyclosporin Capsules, Rituximab, SNP-ACTH (1-39) Gel, Zanubrutinib, Tacrolimus, SHR1459, Placebo, Obinutuzumab, Tacrolimus, Methylprednisolone, Filgotinib, Lanraplenib, belimumab, povetacicept, WAL0921

• Launching multiple stage Membranous Nephropathy pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Membranous Nephropathy Market Overview:

The Membranous Nephropathy Drugs Market report provides current treatment practices, emerging drugs, Membranous Nephropathy market share of the individual therapies, current and forecasted Membranous Nephropathy market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Membranous Nephropathy treatment market practice/algorithm, Membranous Nephropathy market drivers and market barriers and Membranous Nephropathy unmet needs to curate best of the opportunities and assesses the underlying potential of the Membranous Nephropathy drugs market.

Membranous Nephropathy Drugs Uptake and Pipeline Development Activities:

The drugs uptake section highlights the adoption rate of newly launched or anticipated drugs during the study period. The report includes information on market uptake by drugs, patient uptake by therapies, and sales for each drug. Additionally, it offers insights into the Fabry Disease pipeline, examining therapeutic candidates at various stages and the key companies engaged in their development.

Membranous Nephropathy Therapies and Key Companies:

• Placebo: argenx

• VB119: Tenet Medicines

• Rituximab: Mayo Clinic

• MIL62, Cyclosporine: Beijing Mabworks Biotech Co., Ltd.

• B007, Cyclosporin Capsules: Shanghai Jiaolian Drug Research and Development Co., Ltd

• Rituximab, SNP-ACTH (1-39) Gel: Cerium Pharmaceuticals, Inc.

• Zanubrutinib, Tacrolimus: BeiGene

• SHR1459, Placebo: Reistone Biopharma Company Limited

• Obinutuzumab, Tacrolimus, Methylprednisolone: Hoffmann-La Roche

• Filgotinib, Lanraplenib: Gilead Sciences

• Belimumab: GlaxoSmithKline

• Povetacicept: Alpine Immune Sciences, Inc.

• WAL0921: Walden Biosciences

For more information about Membranous Nephropathy companies working in the treatment market, visit Membranous Nephropathy Clinical Trials

Membranous Nephropathy Epidemiology:

The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2019 to 2032. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Membranous Nephropathy.

Membranous Nephropathy Epidemiology Segmentation:

The Membranous Nephropathy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Membranous Nephropathy

• Prevalent Cases of Membranous Nephropathy by severity

• Gender-specific Prevalence of Membranous Nephropathy

• Diagnosed Cases of Episodic and Chronic Membranous Nephropathy

Membranous Nephropathy Market Drivers and Barriers:

The Membranous Nephropathy Market Forecast report highlights key drivers and barriers shaping the Membranous Nephropathy market dynamics, providing insights into factors influencing growth and challenges that may be encountered.

Scope of the Membranous Nephropathy Market Report:

• Study Period: 2019–2032

• Coverage: 7MM (The United States, EU5, and Japan)

• Key Membranous Nephropathy Companies: Argenx, Zai Lab Pty Ltd., Shanghai Jiaolian Drug Research and Development Co. Ltd., Shanghai Pharmaceuticals Holding Co., Ltd, Acelyrin, Beijing Mabworks Biotech Co., Ltd., Cerium Pharmaceuticals Inc., BeiGene, Reistone Biopharma Company Limited, Hoffmann-La Roche, Gilead Sciences, Mallinckrodt, Mayo Clinic, Genentech Inc., GlaxoSmithKline, Roche Pharma AG, Apellis Pharmaceuticals Inc., and others.

• Key Membranous Nephropathy Therapies: placebo, VB119, Rituximab, MIL62, Cyclosporine, B007, Cyclosporin Capsules, Rituximab, SNP-ACTH (1-39) Gel, Zanubrutinib, Tacrolimus, SHR1459, Placebo, Obinutuzumab, Tacrolimus, Methylprednisolone, Filgotinib, Lanraplenib, belimumab, povetacicept, WAL0921

• Membranous Nephropathy Therapeutic Assessment: Current marketed and emerging therapies

• Membranous Nephropathy Market Dynamics: Membranous Nephropathy Market drivers and Membranous Nephropathy barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Membranous Nephropathy Unmet Needs: Insights into unmet needs, KOL’s views, Analyst’s views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Membranous Nephropathy market outlook, drug uptake, treatment scenario, and epidemiology trends, Membranous Nephropathy Market Forecast

About DelveInsight:

DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:

Company Name: DelveInsight Business Research LLP

Contact Person: Ram Kapoor

Email: info@delveinsight.com

Contact No.: +91-9650213330

City: 304 S. Jones Blvd #2432, Las Vegas

State: Nevada (89107)

Country: United States

Website: https://www.delveinsight.com/consulting

The market size of Smoking Cessation and Nicotine Addiction is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Embera NeuroTherapeutics, Inc, Axsome Therapeutics, Currax Pharmaceuticals LLC, Omeros Corporation and others…

[Las Vegar, United States] – DelveInsight’s “Smoking Cessation and Nicotine Addiction Market Insights, Epidemiology, and Market Forecast 2034.” The report offers a detailed examination of Smoking Cessation and Nicotine Addiction, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Smoking Cessation and Nicotine Addiction Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Smoking Cessation and Nicotine Addiction Market Forecast

Key Findings from the Smoking Cessation and Nicotine Addiction Market Report:

• The Smoking Cessation and Nicotine Addiction market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2019-2032).

• In August, 2024: Rose Research Center, LLC announced that their randomized double-blind placebo-controlled trial (N=180) will evaluate the impact of combining zonisamide and bupropion on the process of switching from combustible cigarettes (CCs) to an e- cigarette.

• In July,2024: Achieve Life Sciences announced that the purpose of their study is to assess the long-term 3 mg cytisinicline three times daily (TID) exposure for 52 weeks.

• In March, 2024: Achieve Life Sciences announced that a Phase 3 study is being conducted at sites within the United States to evaluate 3 mg cytisinicline TID for treatment duration of 42 days/6 weeks as well as repeating that duration for a total of 84 days /12 weeks treatment.

• As per the assessment of DelveInsight, the total prevalent cases of smoking cessation in the 7MM were 46,814,225 in 2022, out of which the US accounted for 23,145,916 cases. These cases are anticipated to decrease during the forecasted period (2023-2032).

• Gender-specific prevalent cases of tobacco use were higher in males (around 31,040 thousand cases) as compared to females (around 19,846 thousand) in 2023 in the US.

• Key Smoking Cessation and Nicotine Addiction Companies are as followed: Achieve Life Sciences, NFL Biosciences SAS, Embera NeuroTherapeutics, Inc, Axsome Therapeutics, Currax Pharmaceuticals LLC, Omeros Corporation, Promentis Pharmaceuticals, Otsuka Pharmaceutical

• Key Smoking Cessation and Nicotine Addiction Therapies are as follows: CHANTIX/ CHAMTIX (varenicline), ZYBAN (bupropion), Cytisinicline (cytisine), NFL-101, EMB-001, Bupropion, Zonisamide, Placebo

• Launching multiple stage Smoking Cessation and Nicotine Addiction pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Smoking Cessation and Nicotine Addiction Overview:

Nicotine/tobacco dependence is a cluster of behavioral, cognitive, and physiological phenomena that develop after repeated tobacco use and that typically include a strong desire to use tobacco, difficulties in controlling its use, persistence in tobacco use despite harmful consequences, a higher priority given to tobacco use than\ other activities and obligations, increased tolerance and sometimes a physical withdrawal state

Smoking Cessation and Nicotine Addiction Drugs Uptake and Pipeline Development Activities:

The drugs uptake section highlights the adoption rate of newly launched or anticipated drugs during the study period. The report includes an analysis of market uptake by drugs, patient uptake by therapies, and individual drug sales. Additionally, it offers insights into Fabry Disease Pipeline Development Activities, examining therapeutic candidates at different stages and the key companies involved.

Smoking Cessation and Nicotine Addiction Therapies and Key Companies:

• CHANTIX/ CHAMTIX (varenicline): Pfizer

• ZYBAN (bupropion): GlaxoSmithKline

• Cytisinicline (cytisine): Achieve Life Sciences

• NFL-101: NFL Biosciences SAS

• EMB-001: Embera NeuroTherapeutics, Inc.

For more information about Smoking Cessation and Nicotine Addiction companies working in the treatment market, visit Smoking Cessation and Nicotine Addiction Clinical Trials

Smoking Cessation and Nicotine Addiction Epidemiology:

The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2020 to 2034. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Smoking Cessation and Nicotine Addiction.

Smoking Cessation and Nicotine Addiction Epidemiology Segmentation:

The Smoking Cessation and Nicotine Addiction market report provides epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Smoking Cessation and Nicotine Addiction

• Prevalent Cases of Smoking Cessation and Nicotine Addiction by severity

• Gender-specific Prevalence of Smoking Cessation and Nicotine Addiction

• Diagnosed Cases of Episodic and Chronic Smoking Cessation and Nicotine Addiction

Smoking Cessation and Nicotine Addiction Market Drivers and Barriers:

The Smoking Cessation and Nicotine Addiction Market Forecast report highlights key drivers and barriers shaping the Smoking Cessation and Nicotine Addiction market dynamics, providing insights into factors influencing growth and challenges that may be encountered.

Scope of the Smoking Cessation and Nicotine Addiction Market Report:

• Study Period: 2020-2034

• Coverage: 7MM (The United States, EU5, and Japan)

• Key Smoking Cessation and Nicotine Addiction Companies: Achieve Life Sciences, NFL Biosciences SAS, Embera NeuroTherapeutics, Inc, Axsome Therapeutics, Currax Pharmaceuticals LLC, Omeros Corporation, Promentis Pharmaceuticals, Otsuka Pharmaceutical

• Key Smoking Cessation and Nicotine Addiction Therapies: CHANTIX/ CHAMTIX (varenicline), ZYBAN (bupropion), Cytisinicline (cytisine), NFL-101, EMB-001, Bupropion, Zonisamide, Placebo

• Smoking Cessation and Nicotine Addiction Therapeutic Assessment: Current marketed and emerging therapies

• Smoking Cessation and Nicotine Addiction Market Dynamics: Smoking Cessation and Nicotine Addiction Market drivers and Smoking Cessation and Nicotine Addiction barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Smoking Cessation and Nicotine Addiction Unmet Needs: Insights into unmet needs, KOL’s views, Analyst’s views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Smoking Cessation and Nicotine Addiction market outlook, drug uptake, treatment scenario, and epidemiology trends, Smoking Cessation and Nicotine Addiction Market Forecast

About DelveInsight:

DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:

Company Name: DelveInsight Business Research LLP

Contact Person: Ram Kapoor

Email: info@delveinsight.com

Contact No.: +91-9650213330

City: 304 S. Jones Blvd #2432 , Las Vegas

State: Nevada (89107)

Country: United States

Website : https://www.delveinsight.com/consulting

The market size of Sepsis is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Ono Pharmaceutical, Vivacelle Bio, Inotrem, Enlivex Therapeutics, Adrenomed, Shionogi and others…

[Nevada, United States] – DelveInsight’s “Sepsis Market Insights, Epidemiology, and Market Forecast 2034.” report offers a detailed examination of Sepsis, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Sepsis Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Sepsis Market Forecast

Key Findings from the Sepsis Market Report:

• The Sepsis market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2019-2032).

• In August, 2024: Grand Medical Pty Ltd. announced that their Phase 2 study aims to evaluate the efficacy, safety, and pharmacokinetic characteristics of STC314 injection in sepsis patients receiving loading dose and continuous intravenous infusion, determine the optimal therapeutic dose, and provide supporting evidence for phase III clinical trials.

• In August, 2024: Vivacelle Bio announced that the purpose of their study is to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.

• In August, 2024: Novartis announced that the purpose of this Ph2b study is to characterize the dose-response relationship and to evaluate the safety and efficacy of three different single doses of TIN816 in hospitalized adult participants in an intensive care setting with a diagnosis of sepsis -associated acute kidney injury (SA-AKI).

• In May, 2024: Novartis announced that the purpose of their study is to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profile and to evaluate the safety and tolerability of TIN816 in hospitalized adult participants in an intensive care setting with a diagnosis of sepsis -associated acute kidney injury (SA-AKI).

• Key Sepsis Companies are as follows: La Jolla Pharmaceuticals, Par Pharmaceutical, Ono Pharmaceutical, Vivacelle Bio, Inotrem, Enlivex Therapeutics, Adrenomed, Shionogi, Asahi Kasei Pharma Corp., AM-Pharma, ABIONYX Pharma, Revimmune, Baxter Healthcare Corporation, BioMarck Pharmaceuticals

• Key Sepsis Therapies that have been identified are: Giapreza, Vasostrict, Onoact Injection (Landiolol hydrochloride), VBI-S, Nangibotide, Allocetra, Adrecizumab, Fetroja/Fetcroja (Cefiderocol), Recomodulin (ART-123), Recombinant human alkaline phosphatase, CER -001, CYT107, Esmolol, BIO-11006.

• Launching multiple stage Sepsis pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Sepsis Overview:

Sepsis is a life-threatening organ dysfunction that results from the body’s response to infection. If not recognized early and managed promptly, it can lead to septic shock, multiple organ failure and death. It is most frequently a serious complication of infection, particularly in low- and middle-income countries where it represents a major cause of maternal and neonatal morbidity and mortality.

Sepsis Drugs Uptake and Pipeline Development Activities:

The drug uptake section highlights the rate at which newly launched or soon-to-be-launched drugs are adopted during the study period. The report includes data on market uptake by drugs, patient uptake by therapies, and sales figures for each drug. Furthermore, it offers insights into Fabry Disease Pipeline Development Activities, examining therapeutic candidates at various stages and the key companies involved.

Sepsis Therapies and Key Companies:

• Giapreza: La Jolla Pharmaceuticals

• Vasostrict: Par Pharmaceutical

• Onoact Injection (Landiolol hydrochloride): Ono Pharmaceutical

• VBI-S: Vivacelle Bio

• Nangibotide (LR12): Inotrem

• Allocetra: Enlivex Therapeutics

• Adrecizumab: Adrenomed

• Fetroja/Fetcroja (Cefiderocol): Shionogi

• Recomodulin (ART-123): Asahi Kasei Pharma Corp.

• Recombinant human alkaline phosphatase: AM-Pharma

• CER-001: ABIONYX Pharma

• CYT107: Revimmune

• Esmolol (esmolol hydrochloride): Baxter Healthcare Corporation

• BIO-11006: BioMarck Pharmaceuticals

For more information about Sepsis companies working in the treatment market, visit Sepsis Clinical Trials

Sepsis Epidemiology:

The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2019 to 2032. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Sepsis.

Sepsis Epidemiology Segmentation:

The Sepsis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Sepsis

• Prevalent Cases of Sepsis by severity

• Gender-specific Prevalence of Sepsis

• Diagnosed Cases of Episodic and Chronic Sepsis

Sepsis Market Drivers

• Rising incident population

• Technological advancements

• Increased funding for new drug development and clinical trials

• Increasing awareness among common people

• Increasing research activities during the forecast period.

Scope of the Sepsis Market Report:

• Study Period: 2020–2034

• Coverage: 7MM (The United States, EU5, and Japan)

• Key Sepsis Companies: La Jolla Pharmaceuticals, Par Pharmaceutical, Ono Pharmaceutical, Vivacelle Bio, Inotrem, Enlivex Therapeutics, Adrenomed, Shionogi, Asahi Kasei Pharma Corp., AM-Pharma, ABIONYX Pharma, Revimmune, Baxter Healthcare Corporation, BioMarck Pharmaceuticals

• Key Sepsis Therapies: Giapreza, Vasostrict, Onoact Injection (Landiolol hydrochloride), VBI-S, Nangibotide, Allocetra, Adrecizumab, Fetroja/Fetcroja (Cefiderocol), Recomodulin (ART-123), Recombinant human alkaline phosphatase, CER-001, CYT107, Esmolol, BIO-11006

• Sepsis Therapeutic Assessment: Current marketed and emerging therapies

• Sepsis Market Dynamics: Sepsis Market drivers and Sepsis barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Sepsis Unmet Needs: Insights into unmet needs, KOL’s views, Analyst’s views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Sepsis market outlook, drug uptake, treatment scenario, and epidemiology trends, Sepsis Market Forecast

About DelveInsight:

DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:

Company Name: DelveInsight Business Research LLP

Contact Person: Gaurav Bora

Email: info@delveinsight.com

Contact No.: +91-9650213330

City: 304 S. Jones Blvd #2432 , Las Vegas

State: Nevada (89107)

Country: United States

Website: https://www.delveinsight.com /consulting

“Chronic Myeloid Leukemia Pipeline Insight, 2024” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Chronic Myeloid Leukemia Therapeutics Market.

The report provides a detailed description of the Chronic Myeloid Leukemia drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing in the therapeutics segment developments, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Chronic Myeloid Leukemia Clinical Trial Activities and Regulatory Developments in the domain @ Chronic Myeloid Leukemia Companies

Chronic Myeloid Leukemia Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing Chronic Myeloid Leukemia therapies.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Myeloid Leukemia treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging Chronic Myeloid Leukemia drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Chronic Myeloid Leukemia treatment market.

Learn More about the Clinical and Commercial Development Activities in the Chronic Myeloid Leukemia Therapeutics Domain @ Chronic Myeloid Leukemia Therapies

Chronic Myeloid Leukemia Therapeutics Analysis

There are approximately 20+ key companies developing therapies for chronic myeloid leukemia. Currently, AOP Orphan Pharmaceuticals is leading the therapeutics market with its chronic myeloid leukemia drug candidates in the most advanced stage of clinical development.

Chronic Myeloid Leukemia Companies in the Therapeutics Market Includes:

Some of the key companies in the Chronic Myeloid Leukemia therapeutics market include Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, Incyte Corporation, Sana Biotechnology, Novartis, Nerviano Medical Sciences, Sun Pharma Advanced Research Company, and many others

These companies contribute collectively significantly to Chronic Myeloid Leukemia therapeutics, spanning from pioneering research to the development and commercialization of treatments. Their roles encompass various aspects, including drug discovery, clinical trials, and the delivery of innovative therapies that have revolutionized the management of Chronic Myeloid Leukemia, offering improved outcomes and hope to patients worldwide.

Emerging and Marketed Chronic Myeloid Leukemia Therapies Covered in the Report Include:

• Navtemadlin: Kartos Therapeutics

• Ropeginterferon alfa 2b: AOP Orphan Pharmaceuticals

and Many Others

Get an in-depth assessment of the Emerging Therapies and Chronic Myeloid Leukemia Companies Actively Working in the Market @ Chronic Myeloid Leukemia Clinical Trials

The Report Covers the Emerging Chronic Myeloid Leukemia Therapies Under Different Phases of Clinical Development Like –

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage products (Phase I)

• Pre-clinical and discovery stage candidates

• Discontinued and inactive candidates

Route of Administration

The Chronic Myeloid Leukaemia pipeline report provides the therapeutic evaluation of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide

• Peptide

• Small molecule

Request for Sample PDF to Understand More About the Chronic Myeloid Leukemia Treatment Outlook and Future Perspectives @ Chronic Myeloid Leukemia Market

Table of Content

1. Report Introduction

2. Executive Summary

3. Chronic Myeloid Leukemia Current Treatment Patterns

4. Chronic Myeloid Leukemia – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Chronic Myeloid Leukemia Late-Stage Products (Phase-III)

7. Chronic Myeloid Leukemia Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Chronic Myeloid Leukemia Discontinued Products

13. Chronic Myeloid Leukemia Product Profiles

14. Chronic Myeloid Leukemia Companies

15. Chronic Myeloid Leukemia Drugs

16. Dormant and Discontinued Products

17. Chronic Myeloid Leukemia Unmet Needs

18. Chronic Myeloid Leukemia Future Perspectives

19. Chronic Myeloid Leukemia Analyst Review

20. Appendix

21. Report Methodology

Get Detailed Insights About the Reports Offerings @ Chronic Myeloid Leukemia Treatment Outlook

Contact Info:

Ram Kapoor

Executive: Marketing & International Branding

Email: info@delveinsight.com

Contact No: +14699457679

304 S. Jones Blvd #2432 , Las Vegas NV 89107

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.